A5049850151- Pharmaceutical studies and practices
- Pneumocystis jirovecii pneumonia detection and treatment
- Pharmaceutical Practices and Patient Outcomes
- Antifungal resistance and susceptibility
- Medication Adherence and Compliance
- Potassium and Related Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Gastroesophageal reflux and treatments
Hospital Mare de Déu de la Mercè
2022-2023
Hospital Sant Joan de Déu Barcelona
2022
Background: The increasing utilization of proton pump inhibitors (PPIs) in patients without clear medical indications has raised concerns regarding potential risks, highlighting the importance deprescription. However, comparative analyses withdrawal strategies (abrupt vs gradual) this context remain scarce or low quality. Aim: This study aimed to evaluate success rate deprescribing PPIs hospitalized a documented indication and compare proportion treatment restarts based on strategy. Method:...
Objetivo: El objetivo del estudio es evaluar si la desprescripción de medicamentos considerados bajo valor intrínseco como los condroprotectores o SYSADOA, conlleva un empeoramiento sintomático artrosis, incrementándose el consumo analgésicos. Material y métodos: Siguiendo práctica clínica habitual se retiró tratamiento con SYSADOA a pacientes Centro Atención Primaria (población asignada: 34.382 habitantes, 17% mayores 65 años) en base evidencia científica publicada recomendación...
<h3>Background and importance</h3> Invasive fungal infections (IFI) are a major cause of morbidity mortality in immunosuppressed patients. Posaconazole is used for prophylaxis treatment IFI immunocompromised patients, although there scarce data on its pharmacokinetics posology children. Posaconazol dosing schedule our institutional protocol 4 mg/kg (max 400 mg) three times day 6 300 once daily (twice 1) oral suspension tablets, respectively. <h3>Aim objectives</h3> Determine the number...